Bleomycin electroporation therapy
Alternative Names: NeoPulse; OMS ElectroChemotherapy; SECTA therapy; Selective Electrochemical Tumor Ablation therapyLatest Information Update: 24 Sep 2021
At a glance
- Originator Inovio Biomedical Corporation
- Developer Inovio Pharmaceuticals
- Class Antineoplastics; Cytostatic antibiotics; Glycopeptides
- Mechanism of Action DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Suspended Breast cancer; Head and neck cancer; Malignant melanoma
- Discontinued Basal cell cancer; Kaposi's sarcoma; Liver cancer; Pancreatic cancer
Most Recent Events
- 29 Sep 2017 Inovio withdraws a phase III trial in Head and neck cancer prior to enrolment in USA and European Union based on the Data Monitoring Committee's recommendation(Intratumoural) (NCT00198315)
- 28 Sep 2011 OncoSec plans to conduct further clinical studies, based on positive results from clinical trials in Head and neck cancer and Breast cancer
- 26 Sep 2011 Final adverse events and efficacy data from a phase I trial in Breast cancer released by OncoSec Medical